Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01607216 · ClinicalTrials.gov registry record

Functional and Lymphocytic Markers of Respiratory Morbidity in Hyperoxic Preemies

A clinical trial of Bronchopulmonary Dysplasia and Prematurity, sponsored by University of Rochester.

Completed
Registry status
277
Enrollment target
2
Study locations

NCT01607216 is a study of Bronchopulmonary Dysplasia and Prematurity that has completed, run by University of Rochester. The registered enrollment target is 277 participants, above the 227-participant average among 29 other Bronchopulmonary Dysplasia trials with a reported enrollment target (22% higher). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01607216, a study of Bronchopulmonary Dysplasia and Prematurity, has completed, sponsored by University of Rochester.

COMPLETED
Registry status
277 participants
Enrollment target
2
Study locations

Study Summary

This is an observational study that proposes to collect clinical, physiological, cellular and molecular information in an attempt to identify a set of factors that may predict the risk for persistent lung disease in babies born prematurely.

Study Locations (2)

New York

  • Women and Children's Hospital of Buffalo - Buffalo
  • University of Rochester Medical Center - Rochester

Trial Details

FieldValue
Enrollment Target 277 participants
Start Date 2011-08
Est. Completion 2015-07

Sponsor

University of Rochester

636 total trials

What the Registry Record Tells You About NCT01607216

The ClinicalTrials.gov registry entry for NCT01607216 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 277 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 227-participant average among 29 other Bronchopulmonary Dysplasia trials with a reported enrollment target (22% higher). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Bronchopulmonary Dysplasia appearing as the primary indexed condition, and to 0 interventions.

NCT01607216 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT01607216 about?

NCT01607216 is a clinical study titled "Functional and Lymphocytic Markers of Respiratory Morbidity in Hyperoxic Preemies". This is an observational study that proposes to collect clinical, physiological, cellular and molecular information in an attempt to identify a set of factors that may predict the risk for persistent lung disease in babies born prematurely.

What is the current status of trial NCT01607216?

This trial is currently completed. The enrollment target is 277 participants. The study started on 2011-08. Estimated completion is 2015-07.

What conditions does trial NCT01607216 study?

This clinical trial studies the following conditions: Bronchopulmonary Dysplasia, Prematurity, Symptomatic Respiratory Disease.

Who is sponsoring clinical trial NCT01607216?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01607216 being conducted?

This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bronchopulmonary Dysplasia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.